Literature DB >> 23977484

Transapical aortic valve implantation: The Vancouver experience.

Jennifer Higgins1, Jian Ye, Stefan Toggweiler, John G Webb, Anson Cheung.   

Abstract

INTRODUCTION: Off-pump transapical aortic valve implantation (TA-TAVI) through mini-thoracotomy was first performed in Vancouver, Canada in October 2005. The objective of this manuscript is to describe the Vancouver experience with 178 TA-TAVI cases in symptomatic severe aortic stenosis (AS) since 2005.
METHODS: Baseline characteristics and in-hospital outcomes were calculated for the overall cohort. To compare pre-procedure and post-procedure echocardiographic measurements, one way analysis of variance was utilized, followed by Tukey's HSD. In-hospital outcomes were compared between early and late cohorts using Z-test and chi-squared test as appropriate. Kaplan-Meier analysis was used to generate 3-year survival curves. The Log-rank test was used to compare survival between low-risk and high-risk groups, based on STS score.
RESULTS: Between October 2005-March 2012, TA-TAVI was performed in 178 patients. Mean age was 80.5±8.6 years. Congestive heart failure and renal failure were more common in the late cohort, while previous myocardial infarction was more common in the early cohort (P<0.05). Eleven patients (6.2%) had significant intra-operative complications, including death (1.7%), conversion to CPB (3.9%), and valve embolization (1.1%). In-hospital survival was 87.9%. Mean length of hospital stay was 12.2±17.1 days. In-hospital incidence of stroke was 3.4%. Bleeding (20.2% vs. 4.7%) and vascular (14.6% vs. 3.5%) complications were more common in the early cohort. Echocardiography demonstrated a significant increase in aortic valve area and decrease in mean transvalvular gradient post-procedure. These improvements were maintained throughout the 3-year follow-up period. Overall survival was 72.1% at 6 months, 67.7% at 12 months, 55.5% at 24 months, and 47.3% at 36 months. Repeated Kaplan-Meier analysis for the 2 groups stratified by STS score, demonstrated improved survival in the low-risk group (Log-rank P=0.039).
CONCLUSIONS: Among patients with symptomatic severe AS at high risk for conventional AVR, TA-TAVI is a reasonable therapeutic option with acceptable risk. Long-term survival appears to be superior in lower-risk patients.

Entities:  

Keywords:  Transapical aortic valve implantation (TA-TAVI); aortic stenosis (AS)

Year:  2012        PMID: 23977484      PMCID: PMC3741746          DOI: 10.3978/j.issn.2225-319X.2012.06.06

Source DB:  PubMed          Journal:  Ann Cardiothorac Surg        ISSN: 2225-319X


  9 in total

1.  Standardized endpoint definitions for Transcatheter Aortic Valve Implantation clinical trials: a consensus report from the Valve Academic Research Consortium.

Authors:  Martin B Leon; Nicolo Piazza; Eugenia Nikolsky; Eugene H Blackstone; Donald E Cutlip; Arie Pieter Kappetein; Mitchell W Krucoff; Michael Mack; Roxana Mehran; Craig Miller; Marie-angéle Morel; John Petersen; Jeffrey J Popma; Johanna J M Takkenberg; Alec Vahanian; Gerrit-Anne van Es; Pascal Vranckx; John G Webb; Stephan Windecker; Patrick W Serruys
Journal:  J Am Coll Cardiol       Date:  2011-01-07       Impact factor: 24.094

2.  Transapical aortic valve implantation in humans.

Authors:  Jian Ye; Anson Cheung; Samuel V Lichtenstein; Ronald G Carere; Christopher R Thompson; Sanjeewan Pasupati; John G Webb
Journal:  J Thorac Cardiovasc Surg       Date:  2006-05       Impact factor: 5.209

3.  Transcatheter versus surgical aortic-valve replacement in high-risk patients.

Authors:  Craig R Smith; Martin B Leon; Michael J Mack; D Craig Miller; Jeffrey W Moses; Lars G Svensson; E Murat Tuzcu; John G Webb; Gregory P Fontana; Raj R Makkar; Mathew Williams; Todd Dewey; Samir Kapadia; Vasilis Babaliaros; Vinod H Thourani; Paul Corso; Augusto D Pichard; Joseph E Bavaria; Howard C Herrmann; Jodi J Akin; William N Anderson; Duolao Wang; Stuart J Pocock
Journal:  N Engl J Med       Date:  2011-06-05       Impact factor: 91.245

4.  3-dimensional aortic annular assessment by multidetector computed tomography predicts moderate or severe paravalvular regurgitation after transcatheter aortic valve replacement: a multicenter retrospective analysis.

Authors:  Alexander B Willson; John G Webb; Troy M Labounty; Stephan Achenbach; Robert Moss; Miriam Wheeler; Christopher Thompson; James K Min; Ronen Gurvitch; Bjarne L Norgaard; Cameron J Hague; Stefan Toggweiler; Ronald Binder; Melanie Freeman; Rohan Poulter; Steen Poulsen; David A Wood; Jonathon Leipsic
Journal:  J Am Coll Cardiol       Date:  2012-02-22       Impact factor: 24.094

5.  Transapical transcatheter aortic valve implantation in humans: initial clinical experience.

Authors:  Samuel V Lichtenstein; Anson Cheung; Jian Ye; Christopher R Thompson; Ronald G Carere; Sanjeevan Pasupati; John G Webb
Journal:  Circulation       Date:  2006-07-31       Impact factor: 29.690

6.  Early clinical outcomes after transapical aortic valve implantation: a propensity-matched comparison with conventional aortic valve replacement.

Authors:  Jennifer Higgins; Jian Ye; Karin H Humphries; Anson Cheung; David A Wood; John G Webb; Samuel V Lichtenstein
Journal:  J Thorac Cardiovasc Surg       Date:  2011-05-17       Impact factor: 5.209

7.  Six-month outcome of transapical transcatheter aortic valve implantation in the initial seven patients.

Authors:  Jian Ye; Anson Cheung; Samuel V Lichtenstein; Sanjeevan Pasupati; Ronald G Carere; Christopher R Thompson; Ajay Sinhal; John G Webb
Journal:  Eur J Cardiothorac Surg       Date:  2006-11-28       Impact factor: 4.191

8.  Transapical transcatheter aortic valve implantation: follow-up to 3 years.

Authors:  Jian Ye; Anson Cheung; Samuel V Lichtenstein; Fabian Nietlispach; Saad Albugami; Jean-Bernard Masson; Christopher R Thompson; Brad Munt; Robert Moss; Ronald G Carere; W R Eric Jamieson; John G Webb
Journal:  J Thorac Cardiovasc Surg       Date:  2010-05       Impact factor: 5.209

9.  Transapical transcatheter aortic valve implantation: 1-year outcome in 26 patients.

Authors:  Jian Ye; Anson Cheung; Samuel V Lichtenstein; Lukas A Altwegg; Daniel R Wong; Ronald G Carere; Christopher R Thompson; Robert R Moss; Brad Munt; Sanjeevan Pasupati; Robert H Boone; Jean-Bernard Masson; Abdullah Al Ali; John G Webb
Journal:  J Thorac Cardiovasc Surg       Date:  2008-10-23       Impact factor: 5.209

  9 in total
  3 in total

1.  Transapical aortic valve implantation: a reasonable therapeutic option, but not the only alternative to transfemoral approach.

Authors:  Stephane Noble
Journal:  J Thorac Dis       Date:  2013-06       Impact factor: 2.895

2.  Access options for transcatheter mitral valve implantation in patients with prior surgical bioprosthesis.

Authors:  Laura Besola; Anson Cheung; Jian Ye; Myriam Akodad; Andrew Chatfield; Gnalini Sathananthan; Robert Moss; John Webb
Journal:  Ann Cardiothorac Surg       Date:  2021-09

3.  Successful fast track protocol implementation for patients undergoing transapical transcatheter aortic valve implantation.

Authors:  Nestoras Papadopoulos; Ali El-Sayed Ahmad; Marlene Thudt; Stephan Fichtlscherer; Patrick Meybohm; Christian Reyher; Anton Moritz; Andreas Zierer
Journal:  J Cardiothorac Surg       Date:  2016-04-11       Impact factor: 1.637

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.